Kailera Therapeutics completes enrollment in KaiNETIC Phase 3
Kailera Therapeutics announced completion of enrollment in KaiNETIC, its global Phase 3 clinical program of ribupatide injection, a GLP-1/GIP receptor dual agonist.
Kailera Therapeutics announced completion of enrollment in KaiNETIC, its global Phase 3 clinical program of ribupatide injection, a GLP-1/GIP receptor dual agonist.